Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency

Authors

Juthaporn Cowan, Department of Medicine, Division of Infectious Diseases, University of Ottawa, Ottawa, ON, Canada.
Il-Kang Na, Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
André Gladiator, Global Medical Affairs, Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Marta Kamieniak, Global Medical Affairs, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
S Shahzad Mustafa, Rochester Regional HealthFollow

Department

Allergy and Immunology

Document Type

Article

Publication Title

Frontiers in Immunology

Abstract

Subcutaneous (SCIG) and intravenous immunoglobulin (IVIG) replacement are both used to prevent infections in patients with secondary immunodeficiency (SID). Compared with IVIG, SCIG has fewer systemic side effects and, additionally, facilitates home-based treatment. Shared decision-making practice should include discussion of aspects such as patient preference as well as the associated risks and benefits of treatment. We review the available evidence for the use of SCIG treatment in patients with SID, focusing on patient-reported outcomes (PROs). In most studies, there were improvements to health-related quality of life with SCIG treatment, compared with before initiating SCIG without prior IVIG treatment, or after switching to SCIG from IVIG treatment, or a no-SCIG/IVIG cohort. Treatment satisfaction with SCIG was similar between patients with SID and primary immunodeficiency disease. Patient preference and perception assessments highlighted the benefits of SCIG compared with IVIG, such as ease of use and administration, convenience, and time-effectiveness. In addition, many patients self-administered SCIG at home. Such aspects may be of specific benefit to patients with SID and hematological malignancy by reducing the risk of infection exposure in clinical settings. PRO data may be useful during shared decision-making discussions with patients with SID.

First Page

1528414

DOI

10.3389/fimmu.2025.1528414

Volume

16

Publication Date

3-1-2025

Medical Subject Headings

Humans; Patient Reported Outcome Measures; Immunologic Deficiency Syndromes (drug therapy, therapy, immunology); Immunoglobulins, Intravenous (administration & dosage, therapeutic use); Quality of Life; Injections, Subcutaneous; Immunoglobulins (administration & dosage); Treatment Outcome; Infusions, Subcutaneous

PubMed ID

40181959

Recommended Citation

Cowan, J., Na, I., Gladiator, A., Kamieniak, M., & Mustafa, S. S. (2025). Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency. Frontiers in Immunology, 16, 1528414. https://doi.org/10.3389/fimmu.2025.1528414